STO · ADDV-B.ST
ADDvise Group AB (publ)
SEK 1.73+SEK 0.01 (+0.58%)
ADDvise Group AB (publ)’s quoted price sits in the lower half of its reported 52-week range, 34.84% below the high.
Loading market information…
STO · IBT-B.ST · SEK
Stock price, earnings
Quote as of Oct 29, 2026, 04:29 PM UTC. Cached market data; not a live quote.
One-year closing-price history · SEK. Historical prices are not a forecast.
Infant Bacterial Therapeutics AB (publ)’s quoted price sits in the upper half of its reported 52-week range, 19.55% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
BEHIND THE RESULTS
Infant Bacterial Therapeutics AB (publ)’s next earnings report is currently expected on Nov 13, 2026, with estimated earnings per share of -SEK 2.67. The reporting date and estimates may change.
Upcoming dates and analyst estimates may change. Fiscal quarters follow Infant Bacterial Therapeutics AB (publ)’s reporting calendar.
THE COMPANY BEHIND THE TICKER
Infant Bacterial Therapeutics AB (publ) operates as a clinical stage pharmaceutical company develops and markets drugs to prevent serious neonatal diseases affecting premature infants in Sweden. The company's lead drug candidate is IBP-9414, which is in Phase III clinical studies to prevent necrotizing enterocolitis, as well as to improve feeding tolerance in premature infants. It is also developing IBP-1016 for the treatment of gastroschisis, a rare and severe birth abnormality in infants. In addition, its drug candidates include IBP-1118 to prevent retinopathy of prematurity that causes blindness in premature babies; and IBP-1122, indicated to eliminate vancomycin resistant enterococci that cause antibiotic resistant hospital infections. The company was incorporated in 2011 and is based in Stockholm, Sweden.
Latest available per-share figures in SEK. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 01:25 AM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
| -SEK 2.51 |
| SEK 0.00 |
| Q3 2024 | Nov 14, 2024 | -SEK 2.42 | SEK 0.00 |
|---|
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
SEK 1.73+SEK 0.01 (+0.58%)
ADDvise Group AB (publ)’s quoted price sits in the lower half of its reported 52-week range, 34.84% below the high.
SEK 16.76-SEK 0.72 (-4.12%)
SynAct Pharma AB’s quoted price sits in the upper half of its reported 52-week range, 31.87% below the high.
SEK 58.70-SEK 0.30 (-0.51%)
I-Tech AB’s quoted price sits in the lower half of its reported 52-week range, 27.35% below the high.
SEK 1.71+SEK 0.05 (+3.07%)
Oncopeptides AB (publ)’s quoted price sits in the lower half of its reported 52-week range, 72.13% below the high.
SEK 10.70+SEK 0.22 (+2.1%)
Xspray Pharma AB (publ)’s quoted price sits in the lower half of its reported 52-week range, 70.4% below the high.
SEK 3.20+SEK 0.40 (+14.08%)
Senzime AB (publ)’s quoted price sits in the lower half of its reported 52-week range, 48.72% below the high.
SEK 1.67+SEK 0.20 (+13.2%)
Cantargia AB (publ)’s quoted price sits in the lower half of its reported 52-week range, 74.63% below the high.
SEK 14.30+SEK 0.20 (+1.42%)
Corline Biomedical AB’s quoted price sits in the lower half of its reported 52-week range, 29.21% below the high.
